Used in research and therapeutic development targeting TNFRSF21 (DR6), this reference antibody helps study pathways involved in apoptosis, neurodegeneration, and immune regulation. It serves as a critical tool for validating target engagement and biological activity in preclinical models, especially in oncology and neurology drug discovery. Due to its specific binding properties, it supports the development of biologics and biosimilars by providing a benchmark for affinity, specificity, and functional assays. It is also employed in biomarker studies to understand disease mechanisms related to DR6 signaling, such as in Alzheimer’s disease and certain cancers.